{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T19:30:35Z","timestamp":1769455835036,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Limited data are available on antimicrobials exposure and microbiology evolution in pediatric acute myeloid leukemia (AML) patients underwent antimicrobials prophylaxis. To assess the effectiveness of antimicrobials prophylaxis, antibiotic susceptibilities of bacteria, and exposure of antimicrobials during intensive chemotherapy for AML patients, 90 consecutive de novo AML patients aged 0\u201318\u00a0years between January 1, 1997 and March 31, 2018 were enrolled. Vancomycin, ciprofloxacin and voriconazole prophylaxis was administered from January 1, 2010. During the preprophylaxis period, January 1997 to December 2009, 62 patients experienced a total of 87 episodes of bloodstream infection (BSI) and 17 episodes of invasive fungal infection (IFI) among 502 courses of chemotherapy. In contrast, 16 episodes of BSI occurred and no IFIs were reported to occur in 28 patients who received 247 courses of chemotherapy in the prophylaxis period. Patients who received antimicrobial prophylaxis had a significant reduction of BSI, IFI, and febrile neutropenia in comparison with patients without prophylaxis. Exposure to amikacin, carbapenem, amphotericin B was reduced in the prophylaxis period. Imipenem susceptibility of <jats:italic>Enterobacter cloacae<\/jats:italic> as well as vancomycin susceptibility of <jats:italic>Enterococcus<\/jats:italic> species were reduced in the prophylaxis period. At the time of the last follow up, patients with prophylaxis had a better subsequent 5-year overall survival rate than those without prophylaxis. Prophylactic antimicrobials administration in children with AML who undergo chemotherapy can significantly reduce the rates of life-threatening infection, exposure to antimicrobials, and might result in a better outcome.<\/jats:p>","DOI":"10.1038\/s41598-021-00725-5","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T10:04:13Z","timestamp":1635329053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and antimicrobial susceptibility profiles during primary antimicrobial prophylaxis for pediatric acute myeloid leukemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Ting-Chi","family":"Yeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Yin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Huan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Ju","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi-Che","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"725_CR1","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/jco.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan, C. M. et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J. Clin. Oncol. 33, 2949\u20132962. https:\/\/doi.org\/10.1200\/jco.2015.62.8289 (2015).","journal-title":"J. Clin. Oncol."},{"key":"725_CR2","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1200\/jco.19.00327","volume":"37","author":"JE Rubnitz","year":"2019","unstructured":"Rubnitz, J. E. et al. Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: The AML08 multicenter, randomized phase III trial. J. Clin. Oncol. 37, 2072\u20132081. https:\/\/doi.org\/10.1200\/jco.19.00327 (2019).","journal-title":"J. Clin. Oncol."},{"key":"725_CR3","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/cncr.30791","volume":"123","author":"TB Alexander","year":"2017","unstructured":"Alexander, T. B. et al. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer 123, 3791\u20133798. https:\/\/doi.org\/10.1002\/cncr.30791 (2017).","journal-title":"Cancer"},{"key":"725_CR4","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","volume":"32","author":"M Rasche","year":"2018","unstructured":"Rasche, M. et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: A retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 32, 2167\u20132177. https:\/\/doi.org\/10.1038\/s41375-018-0071-7 (2018).","journal-title":"Leukemia"},{"key":"725_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/cncr.28524","volume":"120","author":"TC Yeh","year":"2014","unstructured":"Yeh, T. C. et al. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. Cancer 120, 1255\u20131262. https:\/\/doi.org\/10.1002\/cncr.28524 (2014).","journal-title":"Cancer"},{"key":"725_CR6","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1182\/blood-2007-05-091942","volume":"110","author":"L Sung","year":"2007","unstructured":"Sung, L. et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 110, 3532\u20133539. https:\/\/doi.org\/10.1182\/blood-2007-05-091942 (2007).","journal-title":"Blood"},{"key":"725_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/sj.leu.2403188","volume":"18","author":"T Lehrnbecher","year":"2004","unstructured":"Lehrnbecher, T. et al. Infectious complications in pediatric acute myeloid leukemia: Analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 18, 72\u201377. https:\/\/doi.org\/10.1038\/sj.leu.2403188 (2004).","journal-title":"Leukemia"},{"key":"725_CR8","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/cncr.28688","volume":"120","author":"H Inaba","year":"2014","unstructured":"Inaba, H. et al. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer 120, 1985\u20131992. https:\/\/doi.org\/10.1002\/cncr.28688 (2014).","journal-title":"Cancer"},{"key":"725_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jama.2018.12512","volume":"320","author":"S Alexander","year":"2018","unstructured":"Alexander, S. et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation a randomized clinical trial. JAMA 320, 995\u20131004. https:\/\/doi.org\/10.1001\/jama.2018.12512 (2018).","journal-title":"JAMA"},{"key":"725_CR10","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2019.15702","volume":"322","author":"BT Fisher","year":"2019","unstructured":"Fisher, B. T. et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia a randomized clinical trial. JAMA 322, 1673\u20131681. https:\/\/doi.org\/10.1001\/jama.2019.15702 (2019).","journal-title":"JAMA"},{"key":"725_CR11","doi-asserted-by":"publisher","first-page":"CD004386","DOI":"10.1002\/14651858.CD004386.pub3","volume":"1","author":"A Gafter-Gvili","year":"2012","unstructured":"Gafter-Gvili, A. et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst. Rev. 1, CD004386. https:\/\/doi.org\/10.1002\/14651858.CD004386.pub3 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"725_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/sj.leu.2403979","volume":"20","author":"DC Liang","year":"2006","unstructured":"Liang, D. C. et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia 20, 136\u2013141. https:\/\/doi.org\/10.1038\/sj.leu.2403979 (2006).","journal-title":"Leukemia"},{"key":"725_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/MPH.0b013e31815a05aa","volume":"29","author":"TC Yeh","year":"2007","unstructured":"Yeh, T. C. et al. The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan. J. Pediatr. Hematol. Oncol. 29, 826\u2013831. https:\/\/doi.org\/10.1097\/MPH.0b013e31815a05aa (2007).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"725_CR14","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1128\/AAC.01083-10","volume":"55","author":"PF Troke","year":"2011","unstructured":"Troke, P. F., Hockey, H. P. & Hope, W. W. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 55, 4782\u20134788. https:\/\/doi.org\/10.1128\/AAC.01083-10 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"725_CR15","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v5.0 (CTCAE). NCI, NIH, DHHS. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf (2017)."},{"key":"725_CR16","unstructured":"Centers for Disease Control and Prevention. Bloodstream infection event (central line-associated bloodstream infection and non-central line-associated bloodstream infection). http:\/\/www.cdc.gov\/nhsn\/PDFs\/pscManual\/4PSC_CLABScurrent.pdf (2017)."},{"key":"725_CR17","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"BD Pauw","year":"2008","unstructured":"Pauw, B. D. et al. European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin. Infect. Dis. 46, 1813\u20131821. https:\/\/doi.org\/10.1086\/588660 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"725_CR18","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1200\/JCO.2004.01.191","volume":"22","author":"U Creutzig","year":"2004","unstructured":"Creutzig, U. et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J. Clin. Oncol. 22, 4384\u20134393. https:\/\/doi.org\/10.1200\/JCO.2004.01.191 (2004).","journal-title":"J. Clin. Oncol."},{"key":"725_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1200\/JCO.2000.18.9.1845","volume":"18","author":"AS Gamis","year":"2000","unstructured":"Gamis, A. S. et al. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: A report from the Children\u2019s cancer group study CCG-2891. J. Clin. Oncol. 18, 1845\u20131855. https:\/\/doi.org\/10.1200\/JCO.2000.18.9.1845 (2000).","journal-title":"J. Clin. Oncol."},{"key":"725_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/cncr.23563","volume":"113","author":"B Kurt","year":"2008","unstructured":"Kurt, B. et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 113, 376\u2013382. https:\/\/doi.org\/10.1002\/cncr.23563 (2008).","journal-title":"Cancer"},{"key":"725_CR21","doi-asserted-by":"publisher","first-page":"e01838-17","DOI":"10.1128\/AAC.01838-17","volume":"62","author":"Y Sun","year":"2018","unstructured":"Sun, Y. et al. Adverse effects of intravenous vancomycin-based prophylaxis during therapy for pediatric acute myeloid leukemia. Antimicrob. Agents Chemother. 62, e01838-17. https:\/\/doi.org\/10.1128\/AAC.01838-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"725_CR22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal, S. J. et al. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob. Agents Chemother. 57, 734\u2013744. https:\/\/doi.org\/10.1128\/AAC.01568-12 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"725_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijid.2018.04.794","volume":"71","author":"JY Li","year":"2018","unstructured":"Li, J. Y. et al. Identification and antimicrobial resistance of pathogens for neonatal septicemia in China\u2014A meta-analysis. Int. J. Infect. Dis. 71, 89\u201393. https:\/\/doi.org\/10.1016\/j.ijid.2018.04.794 (2018).","journal-title":"Int. J. Infect. Dis."},{"key":"725_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1136\/archdischild-2012-302033","volume":"98","author":"L Downie","year":"2013","unstructured":"Downie, L. et al. Community-acquired neonatal and infant sepsis in developing countries: Efficacy of WHO\u2019s currently recommended antibiotics\u2014Systematic review and meta-analysis. Arch. Dis. Child. 98, 146\u2013154. https:\/\/doi.org\/10.1136\/archdischild-2012-302033 (2013).","journal-title":"Arch. Dis. Child."},{"key":"725_CR25","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.2013.2922","volume":"309","author":"BM Kuehn","year":"2013","unstructured":"Kuehn, B. M. \u201cNightmare\u201d bacteria on the rise in US hospitals, long-term care facilities. JAMA 309, 1573\u20131574. https:\/\/doi.org\/10.1001\/jama.2013.2922 (2013).","journal-title":"JAMA"},{"key":"725_CR26","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld, A. G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin. Infect. Dis. 52, e56-93. https:\/\/doi.org\/10.1093\/cid\/cir073 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"725_CR27","doi-asserted-by":"publisher","first-page":"976273","DOI":"10.1155\/2012\/976273","volume":"2012","author":"A Dalhoff","year":"2012","unstructured":"Dalhoff, A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip. Perspect. Infect. Dis. 2012, 976273. https:\/\/doi.org\/10.1155\/2012\/976273 (2012).","journal-title":"Interdiscip. Perspect. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00725-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00725-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00725-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:49:57Z","timestamp":1670086197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00725-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00725-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21142"}}